Trial · NCT04023526
Results by group28
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 28
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Complete Remission (CR) | Cusatuzumab 10 mg/kg Plus Azacitidine | 11.76 | 95% Confidence Interval 5.5 to 23.4 | percentage of participants | |
| Percentage of Participants With Complete Remission (CR) | Cusatuzumab 20 mg/kg Plus Azacitidine | 26.92 | 95% Confidence Interval 16.8 to 40.3 | percentage of participants | |
| Percentage of Participants With CR With Partial Hematological Recovery (CRh) | Cusatuzumab 10 mg/kg Plus Azacitidine | 9.8 | 95% Confidence Interval 4.3 to 21 | percentage of participants | |
| Percentage of Participants With CR With Partial Hematological Recovery (CRh) | Cusatuzumab 20 mg/kg Plus Azacitidine | 7.7 | 95% Confidence Interval 3 to 18.2 | percentage of participants | |
| Percentage of Participants With CR Plus CRh | Cusatuzumab 10 mg/kg Plus Azacitidine | 21.6 | 95% Confidence Interval 12.5 to 34.6 | percentage of participants | |
| Percentage of Participants With CR Plus CRh | Cusatuzumab 20 mg/kg Plus Azacitidine | 34.6 | 95% Confidence Interval 23.2 to 48.2 | percentage of participants | |
| Percentage of Participants With CR With Incomplete Recovery (CRi) | Cusatuzumab 10 mg/kg Plus Azacitidine | 7.8 | 95% Confidence Interval 3.1 to 18.15 | percentage of participants | |
| Percentage of Participants With CR With Incomplete Recovery (CRi) | Cusatuzumab 20 mg/kg Plus Azacitidine | 5.8 | 95% Confidence Interval 2 to 15.6 | percentage of participants | |
| Overall Response Rate (ORR) | Cusatuzumab 10 mg/kg Plus Azacitidine | 29.4 | 95% Confidence Interval 18.7 to 43 | percentage of participants | |
| Overall Response Rate (ORR) | Cusatuzumab 20 mg/kg Plus Azacitidine | 40.4 | 95% Confidence Interval 28.2 to 53.9 | percentage of participants | |
| Percentage of Participants With CR Without MRD | Cusatuzumab 10 mg/kg Plus Azacitidine | 1 | Participants | ||
| Percentage of Participants With CR Without MRD | Cusatuzumab 20 mg/kg Plus Azacitidine | 4 | Participants | ||
| Time to First Response | Cusatuzumab 10 mg/kg and Azacitidine | 2.8 | 95% Confidence Interval 2.6 to 3.5 | Months | |
| Time to First Response | Cusatuzumab 20 mg/kg and Azacitidine | 3 | 95% Confidence Interval 2.8 to 3.9 | Months | |
| Duration of First Response | Cusatuzumab 10 mg/kg Plus Azacitidine | 5.6 | 95% Confidence Interval 0.7 to NA | Months | |
| Duration of First Response | Cusatuzumab 20 mg/kg Plus Azacitidine | 13.6 | 95% Confidence Interval 6.3 to NA | Months | |
| Red Blood Cell (RBC) and/or Platelets Transfusion Independence | Cusatuzumab 10 mg/kg Plus Azacitidine | RBC Transfusion Independence | 29.4 | 95% Confidence Interval 17.5 to 43.8 | percentage of participants |
| Red Blood Cell (RBC) and/or Platelets Transfusion Independence | Cusatuzumab 20 mg/kg Plus Azacitidine | RBC Transfusion Independence | 42.3 | 95% Confidence Interval 28.7 to 56.8 | percentage of participants |
| Red Blood Cell (RBC) and/or Platelets Transfusion Independence | Cusatuzumab 10 mg/kg Plus Azacitidine | Platelets Transfusion Independence | 39.2 | 95% Confidence Interval 25.8 to 53.9 | percentage of participants |
| Red Blood Cell (RBC) and/or Platelets Transfusion Independence | Cusatuzumab 20 mg/kg Plus Azacitidine | Platelets Transfusion Independence | 51.9 | 95% Confidence Interval 37.6 to 66 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04023526/results